, Volume 63, Issue 14, pp 1445–1457 | Cite as

Female Sexual Dysfunction

Potential for Pharmacotherapy
  • Jean L. FourcroyEmail author
Leading Article


The act of sex includes a woman's sexual self and self-image, intimate relationships, family, society and culture. The complexities of her environment, sexual and partner history, past relationships, mental health status, current medical problems and hormonal status all play a role. An interdisciplinary consensus conference panel expanded the former Diagnostic and Statistical Manual of Mental Disorders-IV classifications of female sexual dysfunction to include psychogenic and organic causes of desire, arousal, orgasm and sexual pain disorders that cause personal distress.

The US FDA Guidance paper details the recommendations for the clinical development of drugs for the treatment of female sexual dysfunction. In this document, great emphasis is placed on orgasm as a clinical trial endpoint and itwould appear that satisfactory sexual intercourse is of secondary importance to the Agency. However, there is no evidence to suggest that the majority of women correlate their sexual enjoyment and satisfaction with numbers of orgasms or even the likelihood of orgasm during a given sexual interaction. Nonetheless, any drug coming through the regulatory agency in the US will need to follow these recommendations.

Currently, there are six major pharmaceutical therapeutic paths being pursued for treatment of female sexual disorders and/or postmenopausal symptoms. These include dopaminergic agonists and related substances, melanocortin-stimulating hormones, adrenoceptor antagonists, nitric oxide delivery systems, prostaglandins, and androgens. A number of compounds that target these pathways are undergoing development for female sexual dysfunction. The array of pharmacological agents that are being developed for female sexual dysfunction must prove to be efficacious and have a good safety profile at a time when there are increasing worries that hormonal replacement with estrogen and progestogens are not safe. It is unclear if any of these pharmaceutical pathways will prove to be both safe and effective for the treatment of female sexual disorders; however, studies investigating this area will provide important scientific data for the future.


Sexual Dysfunction DHEA Sexual Arousal Sexual Response Female Sexual Function Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



To the many companies who were helpful in identifying current research including: Lilly/ICOS, Nastech Pharmaceutical Company, Inc., Nexmed, Qualilife, Proctor & Gamble, Vivus, Zonagen, Antares Pharma and Cellegy Pharmaceuticals, Inc. Particular thanks to Drs R Basson, D Ferguson and J Heiman. Complicated switch box from Dr R Rosen. The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.


  1. 1.
    Fourcroy J. Issues and priorities in the development of drug treatments for female sexual dysfunction. Int J Impot Res 1998; 10 Suppl. 2: S121–S3PubMedCrossRefGoogle Scholar
  2. 2.
    Basson R. Expand the concepts of the human sex response cycle. J Sex Marital Ther 2001; 27(1): 33–44PubMedCrossRefGoogle Scholar
  3. 3.
    Basson R, Berman J, Burnett A, et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classification. J Urol 2000 Mar; 163: 888–93PubMedCrossRefGoogle Scholar
  4. 4.
    Bancroft J, Graham CA, McCord C. Conceptualizing women's sexual problems. J Sex Marital Ther 2001; 27: 95–103PubMedCrossRefGoogle Scholar
  5. 5.
    Organization of medical consultations. ICUD — NGO in official relationship with the World Health Organization, International Society of Urology, and International Society for Sexual and Impotence Research [online]. Available from URL: www.congress-urology. org [Accessed 2003 Apr 16]Google Scholar
  6. 6.
    American Psychiatric Association. DSM-IV: diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press, 1994Google Scholar
  7. 7.
    Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996 Apr; 23(3): 259–63PubMedCrossRefGoogle Scholar
  8. 8.
    Heiman JR. Female sexual response patterns: interactions of physiological, affective, and contextual cues. Arch Gen Psychiatry 1980 Nov 11; 37: 1311–6PubMedCrossRefGoogle Scholar
  9. 9.
    Simons J, Carey MP. Prevalence of sexual dysfunctions: results from a decade of research. Arch Sex Behav 2001; 30(2): 177–219PubMedCrossRefGoogle Scholar
  10. 10.
    Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States; prevalence and predictors. JAMA 1999; 281(6): 537–44PubMedCrossRefGoogle Scholar
  11. 11.
    Laumann E, Michael R, Michaels S, et al. The social organization of sexuality. Chicago (IL): University of Chicago Press, 1994Google Scholar
  12. 12.
    Frank E, Anderson C, Rubenstein D. Frequency of sexual dysfunction in normal couples. N Engl J Med 1978; 299: 111–5PubMedCrossRefGoogle Scholar
  13. 13.
    Avis N, Stellato R, Crawford S, et al. Is there an association between menopause status and sexual functioning? Menopause 2000; 7(5): 297–309PubMedCrossRefGoogle Scholar
  14. 14.
    Avis N. Sexual function and aging in men and women: community and population-based studies. J Gend Specif Med 2000; 3(2): 37–41PubMedGoogle Scholar
  15. 15.
    The National Council on Aging [online]. Available from URL: [Accessed 2003 Apr 16]
  16. 16.
    Kingsberg SA. The impact of aging on sexual function in women and their partners. Arch Sex Behav 2002; 31(5): 431–7PubMedCrossRefGoogle Scholar
  17. 17.
    Clayton AH. Female sexual dysfunction related to depression and antidepressant medications. Curr Womens Health Rep 2002 Jun; 2(3): 182–7PubMedGoogle Scholar
  18. 18.
    Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19: 67–85PubMedCrossRefGoogle Scholar
  19. 19.
    Fourcroy JL. Androgens and desire pharmacology in women: syllabus and presentation. First Annual Comprehensive Review of Sexual Medicine; 2002 Apr 18–21; VancouverGoogle Scholar
  20. 20.
    Deliganis AV, Maravilla KR, Heiman JR, et al. Female genitalia: dynamic MR imaging with use of MS-325: initial experiences evaluating female sexual response. Radiology 2002; 225(3): 791–9PubMedCrossRefGoogle Scholar
  21. 21.
    Heiman H. Presentation: psychophysiological measurement perspective. First Annual Comprehensive Review of Sexual Medicine; 2002 Apr 18–21; VancouverGoogle Scholar
  22. 22.
    Laan E, Everaerd W. Physiological measures of vaginal vasocongestion. Int J Impot Res 1998 May; 10 Suppl. 2: S107–10PubMedGoogle Scholar
  23. 23.
    US Food and Drug Administration. Guidance for Industry. Female sexual dysfunction: clinical development of drug products for treatment [online]. Available from URL: [Accessed Apr 16]
  24. 24.
    Rosen R, Brown C, Heiman J, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26: 191–208PubMedCrossRefGoogle Scholar
  25. 25.
    Derogatis L, Rosen R, Leiblum S, et al. The female sexual distress scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther 2002; 28(4): 317–30PubMedCrossRefGoogle Scholar
  26. 26.
    Quirk F, Heiman J, Rosen R, et al. Development of a sexual function questionnaire for clinical trials of female sexual dysfunction. J Womens Health Gend Based Med 2002 Apr; 11(3): 277–89PubMedCrossRefGoogle Scholar
  27. 27.
    Rosen RC. Assessment of female sexual dysfunction: review of validated methods. Fertil Steril 2002; 77 Suppl. 5: S89–93PubMedCrossRefGoogle Scholar
  28. 28.
    Crenshaw TL, Goldberg JP. Dopaminergic drugs. In: Crenshaw TL, Goldberg JP, editors. Sexual pharmacology. New York: WW Norton & Company, 1996: 369–88Google Scholar
  29. 29.
    Jensvold MF, Plaut VC, Rojansky N, et al. Sexual side effects of psychotropic drugs in women and men. In: Jensvold MF, Halbreich U, Hamilton JA, editors. Psychopharmacology and women. Washington, DC: American Psychiatric Press Inc, 1996: 323–68Google Scholar
  30. 30.
    Bancroft J. State of the art lecture: inhibitory mechanisms in men and women. First Annual Comprehensive Review of Sexual Medicine; 2002 Apr 18–21; VancouverGoogle Scholar
  31. 31.
    Heaton J. New classification system for erectile dysfunction therapies. J Androl 1998; 19(4): 399–404PubMedGoogle Scholar
  32. 32.
    Gitlin MJ, Sun R, Altshuler L, et al. Bupropion-sustained release as a treatment for SSRI-induced sexual side effects. J Sex Marital Ther 2002 Mar–Apr; 28(2): 131–8PubMedCrossRefGoogle Scholar
  33. 33.
    O'Sullivan JD, Hughes AJ. Apomorphine-induced penile erections in Parkinson's disease. Mov Disord 1998; 13(3): 536–9PubMedCrossRefGoogle Scholar
  34. 34.
    Foreman MM. Disorders of sexual response: pioneering new pharmaceutical and therapeutic opportunities. Expert Opin Investig Drugs 1995; 4(7): 621–36CrossRefGoogle Scholar
  35. 35.
    Alcantarra AG. A possible dopaminergic mechanism in the serotonergic antidepressant-induced sexual dysfunctions. J Sex Marital Ther 1999; 25(2): 125–9Google Scholar
  36. 36.
    Foreman MM, Hall JL. Effects of D2-dopaminergic receptor stimulation on male rat sexual behavior. J Neural Transm 1987; 68: 153–70PubMedCrossRefGoogle Scholar
  37. 37.
    Everaerd W, Laan E. Drug treatments for women's sexual disorders. J Sex Res 2000; 37(3): 195–204CrossRefGoogle Scholar
  38. 38.
    Wessells H, Gralnek D, Dorr R, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000; 56(4): 641–6PubMedCrossRefGoogle Scholar
  39. 39.
    Wessells H, Fuclarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol 1998; 160(2): 389–93PubMedCrossRefGoogle Scholar
  40. 40.
    Rosen RC, Phillips NA, Gendrano NC. Oral phentolamine and female sexual arousal disorder: a pilot study. J Sex Marital Ther 1999; 25: 137–44PubMedCrossRefGoogle Scholar
  41. 41.
    Palatin Technologies [online]. Available from URL: www.palatin. com [Accessed 2003 April 16]Google Scholar
  42. 42.
    Rubio-Aurioles E, Rampazzo C, Hurley D, et al. Combination therapy for female arousal disorder: a clinical trial to evaluate the efficacy of a combination of phentolamine mesylate and apomorphine in the subjective response to video sexual stimulation [abstract]. Female Sexual Function Forum; 2001 Oct 25–28; Boston (MA), 84Google Scholar
  43. 43.
    Rubio-Aurioles E, Lopez M, Lipezker M, et al. Phentolamine mesylate in postmenopausal women with female sexual arousal disorder: a psychophysiological study. J Sex Marital Ther 2002; 28 Suppl. 1: 205–15CrossRefGoogle Scholar
  44. 44.
    Physicians Desk Reference (PDR). 57th ed. Montvale (NJ): Thomson PDR, 2003Google Scholar
  45. 45.
    Gittelman M, Costabile RA, Peterson C, et al. In clinic evaluation of the safety and efficacy of topical alprostadil (PGE1) for the treatment of female sexual dysfunction [abstract 603]. J Urol 2002; 167(4): 151Google Scholar
  46. 46.
    Islam A, Mitchel JT, Rosen R, et al. Topical alprostadil in the treatment of female sexual arousal disorder: a pilot study. J Sex Marital Ther 2001; 27: 541–9CrossRefGoogle Scholar
  47. 47.
    NexMed (USA), Inc. [online]. Available from URL: [Accessed 2003 May29]
  48. 48.
    Krane R, Brock G, Eardley I, et al. Committee 8 oral nonendocrine treatment. In: Jardin A, Wagner G, Khoury S, et al., editors. Erectile dysfunction. Plymouth: Plymbridge Distributors Ltd, 2000: 730Google Scholar
  49. 49.
    Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction: Sildenatfil Study Group. N Engl J Med 1998; 338(20): 1397–404PubMedCrossRefGoogle Scholar
  50. 50.
    Laan E, van Lunsen RHW, Everaerd W, et al. The enhancement of vaginal vasocongestion by sildenafil in healthy premenopausal women. J Womens Health Gend Based Med 2002; 11(4): 357–66PubMedCrossRefGoogle Scholar
  51. 51.
    Basson R, Mclnnes R, Smoith M, et al. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002; 11(4): 367–77PubMedCrossRefGoogle Scholar
  52. 52.
    Kaplan SA, Reis RB, Kohn IJ, et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology 1999; 53: 481–6PubMedCrossRefGoogle Scholar
  53. 53.
    Caruso S, Intelisano G, Lupo L, et al. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, crossover, placebo-controlled study. Br J Obstet Gynaecol 2001; 108: 623–8CrossRefGoogle Scholar
  54. 54.
    Sipski ML, Rosen RC, Alexander CJ, et al. Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injuries. Urology 2000; 55: 812–5PubMedCrossRefGoogle Scholar
  55. 55.
    Novavax, Inc. [online]. Available from URL: [Accessed 2003 May 29]
  56. 56.
    Meston CM, Worcel M. The effects of yohimbine plus Larginine glutamate on sexual arousal in postmenopausal women with sexual arousal disorder. Arch Sex Behav 2002; 31(4): 323–32PubMedCrossRefGoogle Scholar
  57. 57.
    Ito T, Trant AS, Polan ML. A double-blind placebo-controlled study of ArginMax, a nutritional supplement for enhancement of female sexual function. J Sex Marital Ther 2001; 27(5): 541–9PubMedCrossRefGoogle Scholar
  58. 58.
    Basson R, Bourgeois-Law G, Fourcroy J, et al. Androgen ‘deficiency’ in women is problematic. Med Aspects Hum Sex 2001 Sep; 1(6): 41–3Google Scholar
  59. 59.
    Grumbach MM, Ducharme JR, Moloshok RE. On the fetal masculination action of certain oral progestins. J Clin Endocrinol Metab 1959; 19: 1369–80PubMedCrossRefGoogle Scholar
  60. 60.
    Kirk JM, Perry LA, Shand WS, et al. Female pseudohermaphroditism due to a maternal adrenocortical tumor. J Clin Encrocrinol Metab 1990; 70: 1280–4CrossRefGoogle Scholar
  61. 61.
    Moore KL, Persaud T. The developing human. 6th ed. Philadelphia (PA): WB Saunders, 1998: 563Google Scholar
  62. 62.
    Bachmann G, Bancroft J, Braunstein G, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002; 77(4): 660–5PubMedCrossRefGoogle Scholar
  63. 63.
    Bachmann G, Bancroft J, Braunstein G, et al. Androgen deficiency in women: definition, diagnosis and classification. Princeton Meeting; 2001 Jun 29; Princeton (NJ)Google Scholar
  64. 64.
    Bancroft J. Sexual effects of androgens in women: some theoretical considerations. Fertil Steril 2002 Apr; 77 Suppl. 4: 55–9CrossRefGoogle Scholar
  65. 65.
    Women's Health Initiative Clinical Trial Writing Group. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288(3): 321–33CrossRefGoogle Scholar
  66. 66.
    Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343(10): 682–8PubMedCrossRefGoogle Scholar
  67. 67.
    Mazer NA. Testosterone deficiency in women: etiologies, diagnosis, and emerging treatments. Int J Fertil 2002; 47(2): 77–86Google Scholar
  68. 68.
    Cellegy Pharmaceuticals Inc [online]. Available from URL: [Accessed 2003 Apr 16]
  69. 69.
    Antares Pharma [online]. Available from URL: [Accessed 2003 Apr 16]
  70. 70.
    Phillips E, Bauman C. Safety surveillance of esterified estrogens-methyltestosterone (estratest and estratest HS) replacement therapy in the United States. Clin Ther 1997; 19(5): 1070–84PubMedCrossRefGoogle Scholar
  71. 71.
    Noven Pharmaceuticals, Inc. [online]. Available from URL: [Accessed 2003 May 29]
  72. 72.
    Arlt W, Callies F, Vlumen JCV, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999; 341(14): 1013–20PubMedCrossRefGoogle Scholar
  73. 73.
    Barnhart KT, Freeman E, Grisso JA, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999; 84: 3896–902PubMedCrossRefGoogle Scholar
  74. 74.
    Miller KK. Androgen deficiency in women. J Clin Endocrinol Metab 2001; 86: 2395–401PubMedCrossRefGoogle Scholar
  75. 75.
    US Food and Drug Administration. Dietary Supplement Health and Education Act Public Law 103-417 1994 [online]. Available from URL: [Accessed 2003 Apr 16]
  76. 76.
    Ferguson D. Randomized, placebo-controlled, double blind, crossover design trial of the efficacy and safety of Zestra for women in women with, and without, female sexual arousal disorder. J Sex Marital Ther 2003; 29(1): 33–44PubMedCrossRefGoogle Scholar
  77. 77.
    Grand Opening [online]. Available from URL: [Accessed 2003 Apr 4]

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Uniformed Services University Health SciencesBethesdaUSA

Personalised recommendations